Bristol-myers Squibb Stock Intrinsic Value – Bristol-Myers Squibb Receives Priority Review for Urothelial Cancer Combination Therapy

🌧️Trending News

BRISTOL-MYERS ($NYSE:BMY): Bristol-Myers Squibb, an American biopharmaceutical company, recently received priority review from the U.S. Food and Drug Administration for its combination therapy drug for urothelial cancer. The drug contains nivolumab, a PD-1 immune checkpoint inhibitor, and ipilimumab, an anti-CTLA-4 antibody. The company is hoping to gain accelerated approval of their drug, which could potentially help treat advanced cases of urothelial cancer. Bristol-Myers Squibb has been providing innovative medicines and biopharmaceuticals for decades. It is one of the leading companies in the world known for its research and development of treatments for illnesses and diseases.

In addition, the company is well-known for its leadership in biopharmaceuticals, such as cancer, hepatitis C, cardiovascular disease, diabetes, and immunoscience. The company has strong presence in the U.S. and Europe, and has established strong relationships with healthcare providers, governments, and other stakeholders. It is important to note that Bristol-Myers Squibb is a public company and is listed on the New York Stock Exchange (NYSE: BMY). The stock price of the company has been relatively stable over the past year, with slight fluctuations due to news related to their drug approvals and other developments. Investors should review the company’s financials and potential risks before investing in any stock, including Bristol-Myers Squibb.

Stock Price

On Tuesday, shares of BRISTOL-MYERS SQUIBB opened on the New York Stock Exchange at $49.8, then closed at $50.2, representing a 0.5% increase from the previous closing price of 50.0. The stock’s uplift came after the company received a Priority Review from the U.S. Food and Drug Administration for its combination therapy for treating advanced urothelial cancer, a type of bladder cancer. If approved, this combination therapy could mark a significant milestone for BRISTOL-MYERS SQUIBB in providing more options for patients suffering from this type of cancer. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Bristol-myers Squibb. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Bristol-myers Squibb. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Bristol-myers Squibb. More…

Key Ratios Snapshot

Some of the financial key ratios for Bristol-myers Squibb are shown below. More…

Analysis – Bristol-myers Squibb Stock Intrinsic Value

At GoodWhale, we have conducted a financial analysis of BRISTOL-MYERS SQUIBB. Through our proprietary Valuation Line approach, we were able to calculate the fair value of BRISTOL-MYERS SQUIBB’s stock to be around $69.6. Currently, the company’s stock is being traded at $50.2, resulting in a 27.8% undervaluation. Our analysis indicates that investors should consider buying BRISTOL-MYERS SQUIBB shares at the current price, as there is a potential for long-term upside. More…

Peers

The company was founded in 1887 and is headquartered in New York City. The company’s products are sold in over 100 countries. Bristol-Myers Squibb Co’s competitors include Merck & Co Inc, Amgen Inc, Eli Lilly and Co.

– Merck & Co Inc ($NYSE:MRK)

Merck & Co Inc is a global health care company that offers a wide range of products and services to customers in more than 140 countries. The company has a market cap of 236.25B as of 2022 and a Return on Equity of 28.84%. Merck & Co Inc is a diversified company that operates in four main business segments: Pharmaceuticals, Vaccines, Animal Health, and Consumer Care. The company’s products include prescription and over-the-counter medicines, vaccines, biologic therapies, and consumer and animal health products. Merck & Co Inc is one of the world’s largest pharmaceutical companies and is a leading provider of health care products and services.

– Amgen Inc ($NASDAQ:AMGN)

Amgen Inc is a large biotechnology company with a market cap of 132.76B as of 2022. The company has a strong return on equity of 460.37%. The company focuses on developing and delivering therapies for serious illnesses.

– Eli Lilly and Co ($NYSE:LLY)

Eli Lilly and Co is a pharmaceutical company with a market cap of 312.88B as of 2022. Its return on equity is 45.88%. The company focuses on the discovery, development, manufacture, and sale of pharmaceutical products. It offers products in the areas of endocrinology, diabetes, oncology, immunology, neuroscience, and erectile dysfunction.

Summary

Bristol-Myers Squibb (BMS) recently received priority review from the FDA for a combination therapy to treat urothelial cancer. This therapy, a combination of two drugs, nivolumab and ipilimumab, is expected to significantly improve patient prognosis and treatment outcomes. BMS is well-positioned in the healthcare sector, with a strong portfolio of products and a steady pipeline of new therapies. The company has a healthy balance sheet, ample liquidity and a strong financial position, making it an attractive investment for long-term investors.

In addition, its recent acquisitions and partnerships have diversified BMS’s product offering and expanded its reach in the global market. Furthermore, BMS’s presence in the lucrative biotechnology sector has further strengthened its financial outlook. All these factors indicate that BMS is a good stock pick for investors seeking a long-term asset with strong growth potential.